Welcome to DU!
The truly grassroots left-of-center political community where regular people, not algorithms, drive the discussions and set the standards.
Join the community:
Create a free account
Support DU (and get rid of ads!):
Become a Star Member
Latest Breaking News
General Discussion
The DU Lounge
All Forums
Issue Forums
Culture Forums
Alliance Forums
Region Forums
Support Forums
Help & Search
Health
Related: About this forumWhose interests is the FDA protecting? Not Lyme patients, apparently
On July 31, the FDA announced it would move forward with regulations to restrict cutting edge laboratory developed tests (LDTs), which have not required FDA approval before because they are not marketed to consumers. The new regulations would change that. Why should you care?
Because LDTs include the Lyme tests manufactured by IGeneX and Advanced Laboratory Services that many patients rely on for accurate diagnosis.
The FDAs announcement came on the heels of a July 2014 letter sent by five U.S. Senators to the budget office, urging action on the FDAs draft guidance, which has been under review for several years. The letter specifically calls out Lyme disease testing.
Because LDTs include the Lyme tests manufactured by IGeneX and Advanced Laboratory Services that many patients rely on for accurate diagnosis.
The FDAs announcement came on the heels of a July 2014 letter sent by five U.S. Senators to the budget office, urging action on the FDAs draft guidance, which has been under review for several years. The letter specifically calls out Lyme disease testing.
The problem is that the FDA approved tests for Lyme disease are notoriously insensitive and have been shown to miss more than 50% of Lyme disease cases. (Here) Currently, the FDA has approved 84 Lyme tests, which are produced by 28 companies. (List here) Approximately 90% of these are ELISA tests, which is the first test required under the CDC two-tiered lab test recommendations for Lyme disease. However, researchers have found that the ELISA is too insensitive to be used for screening: Our data indicated that the sensitivity and specificity of the currently used tests for Lyme disease are not adequate to meet the two-tier test approach being recommended.
-
(Link)
InfoView thread info, including edit history
TrashPut this thread in your Trash Can (My DU » Trash Can)
BookmarkAdd this thread to your Bookmarks (My DU » Bookmarks)
3 replies, 1945 views
ShareGet links to this post and/or share on social media
AlertAlert this post for a rule violation
PowersThere are no powers you can use on this post
EditCannot edit other people's posts
ReplyReply to this post
EditCannot edit other people's posts
Rec (4)
ReplyReply to this post
3 replies
= new reply since forum marked as read
Highlight:
NoneDon't highlight anything
5 newestHighlight 5 most recent replies
Whose interests is the FDA protecting? Not Lyme patients, apparently (Original Post)
kickysnana
Aug 2014
OP
The attack on Lyme patients will go down in history as one of the most monstrous crimes ever
lagomorph777
Mar 2016
#3
zazen
(2,978 posts)1. the IDSA attack on Lyme patients and Lyme-literate docs is just bizarre
I was "fortunate" enough to be seropositive by CDC guidelines and still barely got treatment. The invalidation of Lyme and its symptoms is scandalous. And ironically it gives rise to quacks who do offer harmful treatments because we don't have enough research funding, insurance coverage, and legal cover for mainstream doctors, who are afraid to offer anything more than 3 weeks of antibiotics for fear of ostracism or, worse, multimillion lawsuits and loss of licensure (witness the case in NC).
kickysnana
(3,908 posts)2. All of that. I am so weary of this fight but...n/t
lagomorph777
(30,613 posts)3. The attack on Lyme patients will go down in history as one of the most monstrous crimes ever
By the way did you know you can see the Lyme spirochete in your own blood? Fuck the deliberately biased tests. All you need is a good microscope and a lancet of the type used by diabetics to draw blood to test their glucose level.